News
-
-
PRESS RELEASE
Newron reports subscription for EUR 5.5 million of shares by investor group as part of up to EUR 38 million total financing to advance Phase 3 evenamide program
Newron Pharmaceuticals S.p.A. secures EUR 5.5 million from investor group to advance Phase 3 evenamide program, with total financing of up to EUR 38 million -
-
PRESS RELEASE
Newron announces completion of screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals completes screening for enrollment in pivotal Phase 3 ENIGMA-TRS 1 study on evenamide for treatment-resistant schizophrenia patients -
-
-
-
-
-
